A randomised phase II study evaluating the potential molecular profile of biliary tract cancer and also examining the clinical benefit and safety of panitumumab, cisplatin and gemcitabine in the treatment of biliary tract cancer.

Trial Profile

A randomised phase II study evaluating the potential molecular profile of biliary tract cancer and also examining the clinical benefit and safety of panitumumab, cisplatin and gemcitabine in the treatment of biliary tract cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2016

At a glance

  • Drugs Cisplatin; Gemcitabine; Panitumumab
  • Indications Biliary cancer; Gallbladder cancer
  • Focus Therapeutic Use
  • Acronyms TACTIC
  • Most Recent Events

    • 03 Jul 2012 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry.
    • 17 Feb 2012 Planned initiation date changed from 1 Jun 2011 to 1 Jun 2012 as reported by Australian New Zealand Clinical Trials Registry.
    • 25 Mar 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top